Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 4NCT05144997
Official study title

Lorlatinib Continuation Study

Study summary

The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedLorlatinib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 23, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 4

Interventional

Where is it offered?27 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 4
Sponsor
Pfizer
Interventions being studied
Drug: Lorlatinib
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Targeted therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1 - Any participant who is receiving study treatment and deriving clinical benefit (as determined by the Principal Investigator) in a Pfizer-sponsored Lorlatinib Parent Study. 2- Participants must agree to follow the reproductive criteria. 3- Adequate Bone Marrow, Liver, Renal, Pancreatic Function

Reasons someone may not be able to joinExclusion criteria

1 - Female participants who are pregnant or breastfeeding. 2- Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, California
  • The First affiliated Hospital of Anhui Medical UniversityHefei, Anhui
  • Beijing Chest Hospital, Capital Medical UniversityBeijing, Beijing Municipality
  • Beijing Cancer HospitalBeijing, Beijing Municipality
  • Fujian Cancer HospitalFuzhou, Fujian
  • Guangdong Provincial People's HospitalGuangzhou, Guangdong
  • Hunan Provincial Tumor HospitalChangsha, Hunan
  • General Hospital of Eastern Theater CommandNanjing, Jiangsu
  • Jilin Cancer HospitalChangchun, Jilin
  • The first hospital of jilin universityChangchun, Jilin
  • Sir Run Shaw HospitalHangzhou, Qiantang District
  • The Second Affiliated Hospital of PLA Air Force Medical UniversityXi'an, Shaanxi

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 23, 2026. Always confirm current availability with the study team.

View original record ↗